2018 Real-World Evidence benchmarking | Deloitte Insights
Viewing offline content

Limited functionality available

Dismiss
Deloitte UK
  • Services

    Highlights

    • Ecosystems & Alliances

      An engine to embrace and harness disruptive change

    • Our BrightStart Higher Apprenticeship

      Watch our people's stories

    • Responsible Business

      Business needs to change and show the world it’s changed. Explore how with our latest thinking.

    • Audit & Assurance

      • IASPlus
    • Consulting

      • Core Business Operations
      • Customer and Marketing
      • Enterprise Technology & Performance
      • Human Capital
      • Strategy, Analytics and M&A
    • Financial Advisory

      • Mergers & Acquisitions
    • Legal

    • Deloitte Private

      • Family Enterprises
      • Private Equity
      • High Growth
    • Risk Advisory

      • Strategic & Reputation Risk
      • Regulatory Risk
      • Financial Risk
      • Operational Risk
      • Cyber Risk
    • Tax

      • Global Business Tax Services
      • Indirect Tax
      • Global Employer Services
  • Industries

    Highlights

    • Ecosystems & Alliances

      An engine to embrace and harness disruptive change

    • Our BrightStart Higher Apprenticeship

      Watch our people's stories

    • Resilience Reimagined

      Resilient organisations thrive before, during and after adversity. How will you become more resilient?

    • Consumer

      • Automotive
      • Consumer Products
      • Retail, Wholesale & Distribution
      • Transportation, Hospitality & Services
    • Energy, Resources & Industrials

      • Industrial Products & Construction
      • Mining & Metals
      • Oil, Gas & Chemicals
      • Power, Utilities & Renewables
      • Future of Energy
    • Financial Services

      • Banking
      • Capital Markets
      • Insurance
      • Investment Management
      • Real Estate
      • FinTech & Alternative Finance
    • Government & Public Services

      • Health & Social Care
      • Defence, Security & Justice
      • Civil Government
      • Transport
      • International Donor Organisations
    • Life Sciences & Health Care

      • Health Care
      • Life Sciences
    • Technology, Media & Telecommunications

      • Telecommunications, Media & Entertainment
      • Technology
  • Insights

    Deloitte Insights

    Highlights

    • Deloitte Insights app

      Get daily updates on your mobile device

    • Deloitte Review

      Looking ahead, staying ahead

    • By topic

      • AI & cognitive technologies
      • Analytics
      • Blockchain
      • Cyber Risk
      • Digital transformation
      • Diversity & inclusion
      • Human capital
      • Mergers & Acquisitions
      • Private companies
      • Risk management
      • Smart cities
      • Strategy
    • By sector

      • Automotive
      • Consumer products & retail
      • Financial services
      • Government & public services
      • Industrial products
      • Life sciences
      • Oil, gas & chemicals
      • Power & utilities
      • Technology
      • Telecom, media & entertainment
      • Transportation & hospitality
    • Spotlight

      • Brexit
      • Deloitte Review
      • Economics
      • Future of mobility
      • Future of work
  • Careers

    Highlights

    • Our Locations

      Find out more about our locations and what it's like to work across all our offices within the UK

    • Return to Work

      Discover our supported hiring opportunities

    • Women in Technology

      At Deloitte we believe in diversity in all its forms

    • Careers Home

    • Life at Deloitte

    • Professional Careers

    • Early Careers Application

      • Assessment Process
      • Frequently Asked Questions
      • Key Updates & Help
      • Learning & Development
      • Requirements
      • Student & Graduate Events
    • Early Careers Programmes

      • Career Shapers
      • Entry Level Apprenticeship
      • BrightStart Higher Apprenticeship
      • Spring into Deloitte
      • Summer Vacation Scheme
      • Industrial Placements
      • Graduate Programme
    • Early Careers Paths

      • Audit & Assurance
      • Business & Financial Advisory
      • Consulting
      • Cyber
      • Governance, Risk & Regulation
      • Human Capital & Actuarial
      • Legal
      • Real Estate
      • Tax Consulting
      • Technology
  • UK-EN Location: United Kingdom-English  
  • UK-EN Location: United Kingdom-English  
    • Dashboard
    • Saved Items
    • Content feed
    • Profile/Interests
    • Account settings

Welcome back

Still not a member? Join My Deloitte

The future of real-world evidence

by Brett Davis, Jeff Morgan, Sonal Shah
  • Save for later
  • Download
  • Share
    • Share on Facebook
    • Share on Twitter
    • Share on Linkedin
    • Share by email
Deloitte Insights
  • By topic
    By topic
    By topic
    • AI & cognitive technologies
    • Analytics
    • Blockchain
    • Digital transformation
    • Diversity & inclusion
    • Economics
    • Human capital
    • Innovation
    • Leadership
    • Private companies
    • Risk management
    • Strategy
  • By sector
    By sector
    By sector
    • Automotive
    • Consumer products & retail
    • Financial services
    • Government & public services
    • Health care
    • Industrial products
    • Life sciences
    • Mining & metals
    • Oil, gas & chemicals
    • Power, utilities & renewables
    • Technology
    • Telecom, media & entertainment
    • Transportation & hospitality
  • Spotlight
    Spotlight
    Spotlight
    • Combating COVID-19
    • Daily Executive Briefing
    • Deloitte Review
    • Economic weekly update
    • Future of mobility
    • Future of work
    • Industry 4.0
    • Internet of Things
    • Smart cities
    • UK-EN Location: United Kingdom-English  
      • Dashboard
      • Saved Items
      • Content feed
      • Profile/Interests
      • Account settings
    28 June 2018

    The future of real-world evidence Biopharma companies focus on end-to-end, AI-driven, internally developed solutions

    28 June 2018
    • Brett Davis United States
    • Jeff Morgan United States
    • Sonal Shah United States
    • Save for later
    • Download
    • Share
      • Share on Facebook
      • Share on Twitter
      • Share on Linkedin
      • Share by email
    • A focus on end-to-end enterprise solutions
    • Building an in-house engine
    • Investing in talent and technology
    • Overcoming barriers to adoption and value

    ​Biopharma executives are placing greater emphasis on real-world evidence (RWE), a Deloitte life-sciences survey finds. Leaders increasingly must show value for access, understand the patient journey, and provide more data. The survey shows how RWE plays a role.

    Many biopharma companies are increasingly using real-world evidence (RWE)—clinical evidence about a product’s usage, potential benefits, and risks derived from real-world data (RWD)—not only to demonstrate the value of their products but increasingly to address regulatory requirements, drive drug development, support outcomes-based contracts, and reduce products’ time to market. But are they investing enough? What kind of technology, operating model, and talent upgrades are they considering? Do they face any barriers to adoption? What does the future of RWE look like?

    Learn More

    Download the full report

    Read more from the life sciences collection

    Subscribe to receive related content

    Deloitte’s annual RWE benchmarking survey (the inaugural edition published in 2017) studies how these companies are using RWE, what they are investing in, areas of impact, and the hurdles to successful adoption.

    Since we published our first survey, the volume and variety of RWD being generated has continued to expand. Sources now include electronic medical records, health insurance records, genomics, social media, and wearables. The technology platforms and analysis tools available to manage and derive insights continue to evolve, and the application of RWD across the enterprise—and thus the importance biopharma executives are assigning to RWE—has increased. Another important change is that regulatory bodies are working toward providing clarity on the use of RWE for regulatory decision-making. In fact, the FDA has taken steps to provide guidelines around the use of RWE, and is collaborating with the industry to explore its uses.1

    The findings of Deloitte’s second survey not only reflect and elaborate on these changes but also shed light on how 20 leading biopharmaceutical companies are trying to optimize the use of RWE through investment, application, external partnerships, and technology.

    A focus on end-to-end enterprise solutions

    This year’s survey shows that biopharma companies are investing more in RWE capabilities, with a focus on end-to-end solutions that address the entire product life cycle. In the survey, 90 percent of respondents have either already established or are currently investing in building RWE capabilities for use across the entire product life cycle, though only 45 percent currently have capabilities mature enough to do so.

    According to respondents, stakeholder pressure to demonstrate the value of treatments and a shift toward personalized care, as well as new business imperatives such as value-based contracting, novel clinical trial design and execution, and support for regulatory submission, are helping drive this effort.

    Building an in-house engine

    Though biopharma companies have traditionally relied on external vendors for RWD collection and analysis, many are now opting to develop these RWE capabilities in-house: 70 percent of respondents are building or increasing capabilities to conduct more of their RWE studies internally, and 15 percent are building capabilities to exclusively resource studies internally.

    This means more spending on RWE-related talent and technology, and our survey results corroborate this. The two biggest increases in investment over the next year are expected to be in people (30 percent) and technology platforms (25 percent) to support the organization’s RWE capability. Hiring experts to build and implement RWE-enabling systems, such as machine learning systems, may be the prime and immediate focus. But it is also important to make RWD and analytics accessible to a wide range of internal stakeholders, calling for investment in the right technology platforms and external partnerships to democratize the uses and insights that RWD promises.

    Investing in talent and technology

    Like other industries, some biopharma companies are overhauling their IT platforms and strategies to support the big data analytics that are central to RWD analysis and insight. The trend appears to be toward a centralized, largely cloud-based enterprise platform that is capable of data ingestion and integration, advanced analytics, visualization, and knowledge management.

    And as the volume, variety, and velocity of structured and unstructured real-world data grow, artificial intelligence and machine learning will likely be required to adequately capitalize on the potential of health care data to generate life-saving insights such as identifying patients with undiagnosed or underdiagnosed diseases. In our survey, only 60 percent of respondents report currently using machine learning, but almost all—95 percent—expect to use it for RWE in coming years.

    Another interesting trend is the increasing use of nontraditional RWD such as purpose-built linked data (such as clinical data linked to molecular data) and data generated from patients’ wearables or health apps to generate RWE. Evidence generated from these sources could provide quicker and deeper insights into disease progression, treatment pathways, and patient benefit. This trend can also create new opportunities for partnerships with health systems, patient advocacy groups, digital health start-ups, and even patients themselves over time. While less than 60 percent of companies are currently using these data sources, several expect to increase their use in the next 12–18 months.

    Overcoming barriers to adoption and value

    While our research shows that the intent to adopt and apply RWE is there, execution is not easy: 75 percent of respondents said lack of receptivity by external stakeholders such as payers and providers is a major barrier to the development of RWE capabilities, 70 percent cite internal stakeholders’ lack of understanding, and 65 percent, lack of access to the necessary external data.

    Visible buy-in and support from executive-level leadership is necessary to change the company’s mindset and drive broader adoption of real-world data use across the enterprise, while lack of receptivity from external stakeholders can be overcome through transparent communication and new collaborative models for engagement. Strategic partnerships can also be important for the integrated adoption of RWE, especially when it comes to data access.

    An overall solution to all these challenges could be new operating models and governance that can bring about a shift in cultural mindset and breaking down of organizational siloes. Some companies are experimenting with such models.

    As the importance of RWE continues to rise, the answers for biopharma companies seem to lie in enterprisewide technology solutions, new operating models to support end-to-end evidence management, and external partnerships. To learn more about this year’s survey and how RWE is contributing to the changing landscape of biopharma product development, read the complete article on Deloitte Insights.

    Download the full report to read more,
    Mission Critical: Biopharma companies are accelerating real-world evidence adoption, investment, and application

    Authors

    Brett Davis is a principal in the life sciences and health care consulting practice of Deloitte Consulting LLP, and general manager of ConvergeHEALTH by Deloitte. He is based in Philadelphia.

    Jeff Morgan is a specialist leader in Deloitte Consulting LLP and a member of the leadership team of ConvergeHEALTH by Deloitte. He is based in Parsippany, NJ. 

    Sonal Shah is a senior manager with the Deloitte Center for Health Solutions within Deloitte Services LP and leads the center’s life sciences research. She is based in New York.

    Acknowledgments

    The authors would like to thank Terry Hisey for his expertise, support, and guidance. The authors would also like to thank Seb Burnett, David Hardison, Deborshi Dutt, Raveen Sharma, Kristin Feeney, Jodi Reynolds, Mary Cummins, Mike DeLone, Greg Reh, Neil Lesser, Ralph Marcello, Satish Nelanuthula, Ramani Moses, Lauren Wallace, Lynn Sherry, Jon Louis, and many others who contributed their ideas and insights to this project.

     

    Project team: Karla Feghali, manager, ConvergeHEALTH, was instrumental to survey design, recruiting, and interviews; interpreting study results; and editing the report. Wendell Miranda managed survey recruiting, conducted analysis, created charts and graphics, and wrote sections of the report. Leslie Korenda optimized the survey design and led the data analysis. Ryan Carter helped with recruiting, led interviews, and wrote sections of the report. Sanket Surve programmed the survey, analyzed the raw data, and created data tables. Aleks Lazic provided input into the survey design and results.

     

    Cover image by: Gwen Keraval

    Endnotes
      1. Jacqueline Corrigan-Curay, “Real world evidence: A path forward,” U.S. Food & Drug Administration, September, 2017. View in article

    Show moreShow lessShow less

    Topics in this article

    Life Sciences , Health Information Technology , Pharmaceutical , Analytics , Information Management

    Deloitte Center for Health Solutions

    View

    Download Subscribe

    Related

    img Trending

    Interactive 3 days ago

    Jeff Morgan

    Jeff Morgan

    Managing Director | Deloitte Consulting LLP

    Jeff is a managing director in Deloitte Consulting’s life sciences practice with more than 15 years of relevant life sciences experience spanning pharmaceuticals, medical devices, and consulting. He has significant experience helping clients apply real-world data (RWD) across the product life cycle from R&D through commercialization. Jeff has deep knowledge of emerging use cases for RWD and the evolving real-world data landscape. His work has spanned helping clients design enterprise real-world evidence (RWE) strategies, developing new operating models for leveraging RWD, implementing end-to-end evidence analytics platforms, custom applications development, defining governance, and designing new partnership models within the health care ecosystem. He is also the leader of ConvergeHEALTH’s end-to-end evidence offering and solutions.

    • jefmorgan@deloitte.com
    • +1 201 238 7644
    Brett Davis

    Brett Davis

    Principal | ConvergeHEALTH Leader

    Brett is a principal with Deloitte Consulting LLP leading the ConvergeHEALTH offering for Core Industry Solutions. He also serves as the leader of Deloitte Consulting LLP Global Assets. Brett is the general manager (GM) for ConvergeHEALTH by Deloitte, a business focused on creating new health ecosystems to enable the future of health by combining next-generation platforms, deep industry experience, and novel collaboration models. As the GM, he leads ConvergeHEALTH on its mission to support the information-based transformation of health care by helping enable health care and life sciences organizations to answer the “hard questions.” In his role leading Global Consulting Assets, Brett is focused on executing a global strategy to commercially scale assets for Deloitte Consulting LLP, working with strategic alliances and driving commercial go-to-market efforts. Brett serves on the external advisory board of the University of Pennsylvania’s Department of Medical Ethics and Health Policy, as well as the external advisory boards of several organizations.

    • brettdavis@deloitte.com
    • +1 215 405 7682
    Sonal Shah

    Sonal Shah

    Senior Manager | Deloitte Services LP

    Sonal is a senior manager with the Deloitte Center for Health Solutions within Deloitte Services LP and leads the center’s life sciences research. Through her research, she helps inform Deloitte’s health care, life sciences, and government clients about emerging trends, challenges, and opportunities. Her research focuses on R&D and innovation, the impact of the ongoing health care transformation to life sciences companies, and value-based care. Prior to Deloitte, Sonal worked in the biopharma industry. Sonal has a Master of Business Administration in health care management from the Wharton School, and a Doctor of Pharmacy from the Rutgers University Ernest Mario School of Pharmacy.

    • sonshah@deloitte.com
    • +1 212 653 6025

    Share article highlights

    See something interesting? Simply select text and choose how to share it:

    Email a customized link that shows your highlighted text.
    Copy a customized link that shows your highlighted text.
    Copy your highlighted text.

    The future of real-world evidence has been saved

    The future of real-world evidence has been removed

    An Article Titled The future of real-world evidence already exists in Saved items

    Invalid special characters found 
    Forgot password

    OR

    Social login not available on Microsoft Edge browser at this time.

    Connect Accounts

    Connect your social accounts

    This is the first time you have logged in with a social network.

    You have previously logged in with a different account. To link your accounts, please re-authenticate.

    Log in with an existing social network:

    To connect with your existing account, please enter your password:

    OR

    Log in with an existing site account:

    To connect with your existing account, please enter your password:

    Forgot password

    Subscribe

    to receive more business insights, analysis, and perspectives from Deloitte Insights
    ✓ Link copied to clipboard
    • Contact us
    • Careers at Deloitte
    • Submit RFP
    Follow Deloitte Insights:
    Global office directory Office locations
    UK-EN Location: United Kingdom-English  
    About Deloitte
    • Home
    • Press releases
    • Newsroom
    • Deloitte Insights
    • Global Office Directory
    • Office locator
    • Contact us
    • Submit RFP
    Services
    • Audit & Assurance
    • Consulting
    • Financial Advisory
    • Legal
    • Deloitte Private
    • Risk Advisory
    • Tax
    Industries
    • Consumer
    • Energy, Resources & Industrials
    • Financial Services
    • Government & Public Services
    • Life Sciences & Health Care
    • Technology, Media & Telecommunications
    Careers
    • Careers Home
    • Life at Deloitte
    • Professional Careers
    • Early Careers Application
    • Early Careers Programmes
    • Early Careers Paths
    • About Deloitte
    • About Deloitte UK
    • Accessibility statement
    • Cookies
    • Health and Safety
    • Modern Slavery Act Statement
    • Privacy statement
    • Regulators & Provision of Services Regulations
    • Deloitte LLP Subprocessors
    • Supplier Standard Terms & Conditions
    • Terms of Use

    © 2021. See Terms of Use for more information.

     

    Deloitte LLP is the United Kingdom affiliate of Deloitte NSE LLP, a member firm of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”). DTTL and each of its member firms are legally separate and independent entities. DTTL and Deloitte NSE LLP do not provide services to clients. Please see About Deloitte to learn more about our global network of member firms.

     

    Deloitte LLP is a limited liability partnership registered in England and Wales with registered number OC303675 and its registered office at 1 New Street Square, London EC4A 3HQ, United Kingdom.